ClinicalTrials.gg
RecruitingNCT06976606SNAPSHOT- PKP2Updated May 16, 2025

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

An observational study in Arrhythmogenic Cardiomyopathy, PKP2-ACM and PKP2-ARVC, sponsored by Lexeo Therapeutics. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Lexeo Therapeutics · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.

Planned enrollment
76th of 97
40 · median 160
Started
2024
with 11 others
Observational
98 of 231
31 open now
Primary completion
2027-07
later than 20 of 67 live
Registered
202nd of 231
by date
Lead sponsor
6 of 231
Lexeo Therapeutics

Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 76th largest by planned enrollment of the 97 observational ones that give a count, is one of 12 that started in 2024, is one of 98 observational ones, reaches primary completion later than 20 of the 67 other live ones, and was the 202nd registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

Read the detailed description

SNAPSHOT-PKP2 is an observational, multicenter study that consists of 2 parts, a retrospective EMR review (up to 2 years) and a prospective observational study (1 year), to evaluate the clinical burden of illness of patients with PKP2-ACM, and to prospectively evaluate changes in key cardiac parameters and patient-reported outcome measures (PROMs) associated with PKP2-ACM progression.

03

Conditions studied

  • Arrhythmogenic Cardiomyopathy
  • PKP2-ACM
  • PKP2-ARVC

Keywords

  • Arrhythmogenic Cardiomyopathy
  • ACM
  • Cardiomyopathy
  • ARVC
  • Arrhythmogenic Right Ventricular
  • Arrhythmogenic Right Ventricular Dysplasia
  • Genetic cardiomyopathy
  • Gene Therapy
  • PKP2 Gene
  • Plakophilin-2
  • LX2020
  • SNAPSHOT-PKP2
  • Ventricular Arrhythmia
  • PVCs
  • Sudden Cardiac Death
  • Cardiac Arrest
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18-65 years at time of consent with confirmed diagnosis of ACM and documentation of PKP2 variant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
  • Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
  • Frequent premature ventricular contractions (PVCs)
  • Patients must have an ICD placed prior to enrollment
  • (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.

Exclusion criteria

Exclusion Criteria:

  • Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.
  • A history of other cardiac abnormalities as specified in the protocol.
  • symptoms of heart failure of Class IV at the time of consent.
  • A history of prior gene transfer therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
40 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Premature ventricular contractions (PVC)

    Change from baseline

    Time frame: 12 months

Secondary outcomes

  1. Ventricular arrhythmias and associated clinical events

    Change from baseline by interrogation of implanted cardioverter defibrillator and remote cardiac monitoring

    Time frame: 12 months

  2. ECG parameters

    Change from baseline

    Time frame: 12 months

  3. Cardiac structure and function

    Change from baseline via cardiac MRI and echocardiogram

    Time frame: 12 months

  4. Patient reported outcomes

    Patients' Global Impression of Change (PGIC) scale, measuring participant perception of change from baseline.

    Time frame: 12 months

  5. Patient reported outcomes

    Patients' Global Impression of Severity (PGIS) scale, measuring patient perception of disease progression.

    Time frame: 12 months

  6. Cardiac Biomarkers

    Change from baseline

    Time frame: 12 months

  7. Health resource utilization

    Number of ED, urgent care and outpatient visits, and hospitalizations

    Time frame: 12 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2027, 42 months after the start.

Of 141 observational studies under Cardiomyopathies, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 34. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
May 16, 2025
StartActual
Jan 23, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976606
Lead sponsor
Lexeo Therapeutics
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jan 23, 2024
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 16, 2025

Study contacts

Person*: Lexeo Clinical Trials
Contact
clinicaltrials@lexeotx.com
212-547-9879
Lexeo Clinical Trials
study director · Lexeo Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion